Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer

Supportive Care in Cancer

Volumn 7, Issue 4, 1999, Pages 271-279

  Dranitsaris, George ^a   Hsu, Tom ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Economic analysis; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CANADA; CANCER CARE FACILITIES; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITAL COSTS; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MODELS, ECONOMETRIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0032969475     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050260     Document Type: Article

References (19)

1. Coleman RE, Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19:79-103
2. Conti PF, Giannessi PG, Latreille J, et al (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicentre phase III trial. Ann Oncol 5 [Suppl 7]:S1-4
3. Doyle C, Stockler M, Pintilli M, et al (1997) Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 15:1000-1007
4. Edelson JT, Weinstein MC, Tosteson ANA, et al (1990) Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413
5. Elte JWF, Bijvoet OLM, Cleton FJ, et al (1986) Osteolytic bone metastases in breast carcinoma: pathogenesis, morbidity and bisphosphonate treatment. Eur J Clin Oncol 22:493-500
6. Fitton A, McTavish D (1991) Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 289:289-305
7. Hillner BE, Smith TJ (1991) Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 324:160-168
8. Hortobagyi GN, Theriault RL, Porter L, et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
9. Hortobagyi GN, Theriault RL, Lipton A, et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038-2044
10. Johnell JO (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 130:20S-26S
11. Purohit OP, Anthony C, Radstone CR, et al (1994) High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:S59-63
12. Russell LB, Gold MR, Siegel JE, et al (1996) The role of cost-effectiveness analysis in health and medicine. JAMA 276:1172-1177
13. Scher HI, Yagoda A (1987) Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am J Med 82 [Suppl 2a]:6-28
14. Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chron Dis 40:593-600
15. Torrance GW, Blaker D, Detsky A, et al (1996) Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 9:535-559
16. Tretiak R, Laupacis A, Riviere M, et al (1996) The Canadian Cost of Transfusion Study Group. Cost of allogenic and autologous blood transfusion in Canada. Can Med Assoc J 154:1501-1508
17. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, et al (1991) The effect of supportive pamidronate treatment on aspects of quality of life in patients with advanced breast cancer. Eur J Cancer 27:544-549
18. Weinstein MC, Fineberg HV (1980) Clinical decision analysis. Saunders, Philadelphia
19. Zethraues N, Gerdtham UG (1998) Estimating the cost of hip fractures and potential savings. Int J Technol Assess Health Care 14:255-67